INmune Bio Inc. to Announce Q1 2024 Financial Results and Corporate Update on May 9

May 7, 2024 – INmune Bio Inc. (NASDAQ: INMB), a clinical-stage immunology company committed to developing therapies that leverage a patient's immune system to combat diseases, has announced a conference call scheduled for Thursday, May 9, 2024, at 4:30 PM Eastern Time. The purpose of the call is to discuss the company's first-quarter results for the period ending March 31, 2024, and to provide updates on corporate activities.

Conference Call Information

Participants are encouraged to dial in 5 to 10 minutes before the call begins and should request the INmune Bio Fourth Quarter Conference Call upon connecting with the operator. The details for the call are as follows:

Date: May 9, 2024
Time: 4:30 PM Eastern Time
Dial-in: 1-800-343-5172 (Domestic)
Dial-in: 1-203-518-9856 (International)
Conference ID: INMUNE

A live audio webcast of the conference call will be available at the provided link: https://viavid.webcasts.com/starthere.jsp?ei=1666877&tp_key=6505d73fc4. A transcript will be available approximately 24 hours following the call, and a replay of the call can be accessed until May 15th by dialing 1-844-512-2921 (Domestic) or 1-412-317-6671 (International) and entering the PIN 1155727.

About INmune Bio Inc.

INmune Bio, Inc. is a publicly traded biotechnology company at the clinical stage, focusing on creating treatments that engage the innate immune system to battle diseases. The company has two primary product platforms currently undergoing clinical trials:

1. Dominant-Negative Tumor Necrosis Factor (DN-TNF) Platform: This platform employs dominant-negative technology to specifically neutralize soluble TNF, a critical factor in innate immune dysfunction, which is a mechanistic contributor to various diseases. XPRO, the first product from this platform, is in clinical trials to assess its effectiveness in treating patients with Mild Alzheimer’s disease. Future therapeutic applications will include treatment-resistant depression and oncology, contingent on resource availability.

2. Natural Killer Cell Priming Platform: This platform includes INKmune™, a therapy designed to prime a patient's NK cells to treat cancer. Using a precision medicine approach, INKmune targets a broad range of hematologic and solid tumor malignancies. The clinical trial for INKmune is currently enrolling patients in a US Phase I/II trial, particularly men with metastatic castrate-resistant prostate cancer.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!